These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30975914)

  • 1. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
    Boudny M; Zemanova J; Khirsariya P; Borsky M; Verner J; Cerna J; Oltova A; Seda V; Mraz M; Jaros J; Jaskova Z; Spunarova M; Brychtova Y; Soucek K; Drapela S; Kasparkova M; Mayer J; Paruch K; Trbusek M
    Haematologica; 2019 Dec; 104(12):2443-2455. PubMed ID: 30975914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
    Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
    Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
    Zemanova J; Hylse O; Collakova J; Vesely P; Oltova A; Borsky M; Zaprazna K; Kasparkova M; Janovska P; Verner J; Kohoutek J; Dzimkova M; Bryja V; Jaskova Z; Brychtova Y; Paruch K; Trbusek M
    Oncotarget; 2016 Sep; 7(38):62091-62106. PubMed ID: 27556692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
    Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
    Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.
    Samadder P; Suchánková T; Hylse O; Khirsariya P; Nikulenkov F; Drápela S; Straková N; Vaňhara P; Vašíčková K; Kolářová H; Binó L; Bittová M; Ovesná P; Kollár P; Fedr R; Ešner M; Jaroš J; Hampl A; Krejčí L; Paruch K; Souček K
    Mol Cancer Ther; 2017 Sep; 16(9):1831-1842. PubMed ID: 28619751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
    Voltan R; Rimondi E; Melloni E; Rigolin GM; Casciano F; Arcidiacono MV; Celeghini C; Cuneo A; Zauli G; Secchiero P
    Oncotarget; 2016 Oct; 7(43):70623-70638. PubMed ID: 27661115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
    Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
    Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines.
    Verner J; Trbusek M; Chovancova J; Jaskova Z; Moulis M; Folber F; Halouzka R; Mayer J; Pospisilova S; Doubek M
    Leuk Lymphoma; 2015; 56(11):3198-206. PubMed ID: 25827173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
    Guarini A; Peragine N; Messina M; Marinelli M; Ilari C; Cafforio L; Raponi S; Bonina S; Mariglia P; Mauro FR; Gaidano G; Del Giudice I; Foà R
    Br J Haematol; 2019 Feb; 184(3):392-396. PubMed ID: 30338509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.
    Laroche-Clary A; Lucchesi C; Rey C; Verbeke S; Bourdon A; Chaire V; Algéo MP; Cousin S; Toulmonde M; Vélasco V; Shutzman J; Savina A; Le Loarer F; Italiano A
    Ann Oncol; 2018 Apr; 29(4):1023-1029. PubMed ID: 29409053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
    Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D
    Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
    Agathanggelou A; Smith E; Davies NJ; Kwok M; Zlatanou A; Oldreive CE; Mao J; Da Costa D; Yadollahi S; Perry T; Kearns P; Skowronska A; Yates E; Parry H; Hillmen P; Reverdy C; Delansorne R; Paneesha S; Pratt G; Moss P; Taylor AMR; Stewart GS; Stankovic T
    Blood; 2017 Jul; 130(2):156-166. PubMed ID: 28495793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.
    Amin NA; Balasubramanian S; Saiya-Cork K; Shedden K; Hu N; Malek SN
    Clin Cancer Res; 2017 Feb; 23(4):1049-1059. PubMed ID: 27535981
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
    Liu Y; Kwiatkowski DJ
    Mol Cancer Ther; 2015 Jan; 14(1):174-82. PubMed ID: 25349305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
    Isono M; Okubo K; Asano T; Sato A
    Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia.
    Kong C; Wu M; Lu Q; Ke B; Xie J; Li A
    Leuk Res; 2024 Sep; 144():107548. PubMed ID: 39018782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
    Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
    Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
    Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
    Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
    Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
    Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.